An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2018
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Foresee Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 26 Jul 2018 According to a Foresee Pharmaceuticals media release, the last patient out expected in late 2018.
- 03 Jul 2018 Status changed from recruiting to active, no longer recruiting.